The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.
B-cell signalling suppression with tirabrutinib appears to promote remission in patients with refractory pemphigus, as shown in a phase II trial. Furthermore, treatment has reduced oral corticosteroid exposure over time without any major safety concerns.
Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.
A recent study that defined the disease course of penile calciphylaxis has reported high mortality among patients with such condition and suggests imaging to aid in its diagnosis. End-stage renal disease, hyperparathyroidism, and normal body mass index are significantly associated with this rare disorder.
In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.
Use of the cold atmospheric plasma (CAP) device, which generates free radicals through the ionization of air at room temperature, results in significantly improved mild and moderate atopic dermatitis (AD) with no serious safety concerns, a study has shown.
Some skin diseases present with seasonal patterns, including warts, eczema, and atopic dermatitis, a new study has found. Though more common in winter, acne remains the most prevalent diagnosis in dermatology clinics.